Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study.

ABSTRACT:

Aims

We aimed to determine the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting.

Methods

Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023.

Results

The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19-101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserv

SUBMITTER: Kocabas U 

PROVIDER: S-EPMC11769646 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature